DeepRhythmAI vs EchoNext
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 75/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
DeepRhythmAI and EchoNext are adjacent competitors, both leveraging AI for ECG analysis in cardiology. DeepRhythmAI focuses on detecting and classifying cardiac arrhythmias, aiming to improve efficiency and accuracy in rhythm disorder diagnostics. In contrast, EchoNext specializes in identifying hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension from standard ECGs, providing a screening tool for conditions often missed by traditional methods.
Choose DeepRhythmAI if…
Choose DeepRhythmAI if your primary need is highly accurate and efficient detection and classification of a wide range of cardiac arrhythmias from various ECG devices, including Holter, Event, and Mobile Cardiac Telemetry data. This tool is ideal for streamlining clinical workflows and reducing missed diagnoses of critical arrhythmias, offering faster reporting and analysis.
View DeepRhythmAI →Choose EchoNext if…
Choose EchoNext if your focus is on screening for hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension, using standard 12-lead ECGs. This tool is particularly well-suited for early detection in broad patient populations, potentially identifying high-risk conditions that might otherwise be missed by traditional methods and leading to earlier intervention.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | DeepRhythmAI | EchoNext |
|---|---|---|
| Pricing | Enterprise | Starts at $600/month |
| Deployment | Cloud | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | DeepRhythmAI | EchoNext |
|---|---|---|
| Tool Name | DeepRhythmAI | EchoNext |
| Company | Medicalgorithmics S.A. | Pathway Labs |
| Description | FDA-cleared, cloud-based AI algorithm that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians. | FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Functionality | AI-powered arrhythmia detection and classification, utilizing CNN and Transformer models trained on 250 billion+ annotated heartbeats. | AI-powered ECG analysis for detection of hidden structural heart disease, identifying heart failure risk, screening for valve disease, and detecting pulmonary hypertension indicators using standard 12-lead ECGs. |
| Target Size | Solo to large health systems | Broad access, from major hospitals to community practices. |
| API Available | Yes | Not specified |
| Specialties | Cardiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring DeepRhythmAI and EchoNext.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
DeepRhythmAI is designed for seamless integration with existing healthcare workflows and various ECG devices, offering an API for integration with other medical products and computer-based ECG systems. It processes data from Holter, Event, and Mobile Cardiac Telemetry devices, providing results within minutes. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. clinicians, aiming to embed its screening output directly into tools physicians already use at the point of care.
DeepRhythmAI has demonstrated superior sensitivity for arrhythmia detection, with a 14 times lower risk of missing critical arrhythmia diagnoses compared to human technicians. It achieved a negative predictive value exceeding 99.9% for clinically significant arrhythmias. EchoNext, in studies, accurately identified 77% of structural heart problems from ECGs alone, outperforming cardiologists who achieved 64% accuracy, and 69% with AI assistance. Its AUROC was 85.2% in internal tests and 78-80% in external validation.
DeepRhythmAI is specifically designed for revolutionizing cardiac arrhythmia detection and classification from ECG data, making it highly suitable for cardiology and electrophysiology practices focused on rhythm disorders. EchoNext is geared towards detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard 12-lead ECGs, making it relevant for cardiologists, family medicine, hospital medicine, and internal medicine for broader screening purposes.
DeepRhythmAI is a cloud-based software that integrates with existing equipment and software, suggesting a focus on seamless workflow integration to minimize the learning curve. EchoNext is available through the OpenEvidence platform, which aims to integrate the screening output directly into tools physicians already use, potentially reducing the need for extensive new system training.
While specific details on support quality are not extensively provided for either tool, DeepRhythmAI's company, Medicalgorithmics, is a global medtech company operating in over 20 countries, suggesting an established support infrastructure. EchoNext's partnership with OpenEvidence, a platform used by a large number of U.S. clinicians, implies that support might be integrated within the OpenEvidence ecosystem.
The provided information does not explicitly detail the audit-trail features for either DeepRhythmAI or EchoNext. However, DeepRhythmAI's FDA clearance and focus on direct-to-physician reporting for review and confirmation suggest a need for clear record-keeping of AI analysis and physician oversight. EchoNext's role as a screening tool to flag high-risk patients for further imaging would also necessitate robust tracking of AI recommendations and subsequent clinical actions.
DeepRhythmAI is described as scalable for various healthcare organizations and targets solo to large health systems, indicating its suitability for multi-site rollouts. EchoNext is designed for broad access, from major hospitals to community practices, and its availability through the OpenEvidence platform aims to facilitate national-scale implementation across health systems.